Figure 1.
Cox regression analysis of patient survival for the subcohort of 32 patients with metastases, stratified into histopathological groups according to the 2013-SPRING survival prediction model
| B | SE | Exp(B) | 95 % CI for Exp(B) | p-value | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Age [per year] | 0.039 | 0.037 | 1.040 | 0.967 | 1.119 | 0.293 |
| Gender [male = 1] | 0.235 | 0.622 | 1.265 | 0.373 | 4.285 | 0.706 |
| Slow-growing-mets (reference) | 0.022* | |||||
| Fast-growing mets | 1.859 | 0.898 | 6.419 | 1.105 | 37.294 | 0.038* |
| Moderate-growing mets | 0.436 | 1.014 | 1.547 | 0.212 | 11.289 | 0.667 |
| Pathological fx or > 1 mets | -0.683 | 0.725 | 0.505 | 0.122 | 2.093 | 0.346 |
| C-reactive protein [mg/L] | 0.018 | 0.008 | 1.018 | 1.003 | 1.034 | 0.021* |
| Leukocyte count [109/L] | 0.096 | 0.081 | 1.100 | 0.940 | 1.289 | 0.234 |
| Hemoglobin [g/L] | 0.027 | 0.029 | 1.027 | 0.971 | 1.087 | 0.348 |
| Thrombocyte count [109/L] | 0.000 | 0.005 | 1.000 | 0.989 | 1.011 | 0.980 |
Demographic characteristics, oncological stage and observed survival of patients stratified according to the histopathological diagnosis according to the 2013-SPRING survival prediction model
| Fast-growing metastases | Moderate-growing metastases | Slow-growing metastases | Sarcomas | Non-oncological patients | |
|---|---|---|---|---|---|
| No. of subjects | 12 | 11 | 9 | 73 | 39 |
| Mean age [years] | 63 ± 14 | 65 ± 10 | 64 ± 12 | 42 ± 21 | 53 ± 19 |
| Gender [Female/Male] | 6 / 6 | 2 / 9 | 8 / 1 | 39 / 34 | 20 / 19 |
| Percentage of patients with pathological fracture or > 1 metastasis | 75% | 73% | 44% | 18% | 0% |
| Patients alive 2 years after the operation † | 25% | 55% | 88% | 80% | 100% |
| Patients alive 5 years after the operation ‡ | 10% | 30% | 83% | 69% | 97% |
| Implant removed within 2 years after the operation † | 0% | 9% | 13% | 9% | 11% |
| Implant removed within 5 years after the operation ‡ | 10% | 10% | 17% | 18% | 19% |
Cox regression analysis of patient survival for the cohort of 144 patients with tumor endoprosthetic reconstructions, stratified into histopathological groups according to the 2013-SPRING survival prediction model
| B | SE | Exp(B) | 95 % CI for Exp(B) | p-value | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Age [per year] | 0.021 | 0.010 | 1.021 | 1.002 | 1.041 | 0.031* |
| Gender [male = 1] | -0.410 | 0.304 | 0.664 | 0.366 | 1.205 | 0.178 |
| Slow-growing-mets (reference) | 0.002* | |||||
| Fast-growing mets | 1.709 | 0.674 | 5.522 | 1.473 | 20.703 | 0.011* |
| Moderate-growing mets | 0.853 | 0.703 | 2.347 | 0.592 | 9.308 | 0.225 |
| Sarcomas | 0.831 | 0.661 | 2.296 | 0.629 | 8.378 | 0.208 |
| Non-oncological patients | -1.315 | 0.964 | 0.269 | 0.041 | 1.776 | 0.173 |
| Pathological fx or > 1 mets | 1.032 | 0.350 | 2.809 | 1.414 | 5.587 | 0.003* |